Latest News
The Alzheimer’s risk gene APOE4 puts women at greater risk for Alzheimer’s disease than men. New research suggests this may be caused by an interaction between blood and brain immune cells that appears before any cognitive symptoms.
Driven by a desire to make a meaningful impact on public health, National Glaucoma Research grant recipient Dr. Bingrui Wang is developing glaucoma prediction technology and tools for early detection.
BrightFocus Foundation Macular Degeneration Research grant recipient Maximilian Pfau, MD, aims to bridge this gap in available testing for AMD and detect the condition as early as possible. Learn more about his Macular Degeneration Research-funded project.
In This Issue:
- FDA Approves First-of-its-Kind Glaucoma Treatment
- President’s Corner
- AI Identifies New Genetic Targets for Glaucoma Treatment
- Six Common Glaucoma Eye Tests
- And more!
Alzheimer’s Disease Research, a BrightFocus Foundation program, was on the ground at the 2024 Alzheimer’s Association International Conference (AAIC) in Philadelphia to share insights on the latest research and foster scientific collaboration. Catch up on a few of the top headlines from AAIC.
In glaucoma, problems with mitochondria—a source of cell energy—can damage neurons that carry visual information from the eyes to the brain. Adriana Di Polo, PhD, is testing small molecule drugs that may prevent this damage and boost energy production in these neurons.
A new BrightFocus-funded study of cognitively healthy 100-year-olds sheds light on genetic characteristics that protect the brain.
Increased eye inflammation with age may contribute to macular degeneration and present differently between sexes, suggests a new BrightFocus-funded study.
In This Issue:
- President’s Corner
- Alzheimer’s Drugs in the News
- Researcher Spotlight: Matthew Isaacson, PhD
- And More!
Another disease-modifying Alzheimer's therapy hits the market.
